Bookrunner BofA Merrill Lynch also has $10.69 million greenshoe
By Devika Patel
Knoxville, Tenn., June 20 - Repros Therapeutics Inc. said it priced a $71.25 million public sale of stock with a $10.69 million greenshoe. The deal was announced Tuesday.
The company priced 3.75 million common shares at $19.00 per share. The price per share is a 1.04% discount to the June 19 closing share price of $19.20.
BofA Merrill Lynch is the bookrunner.
Settlement is expected June 25.
Proceeds will be used for general corporate purposes, including clinical trials for Androxal and Proellex.
Repros Therapeutics develops drugs for the treatment of reproductive disorders. The company is based in the Woodlands, Texas.
| Issuer: | Repros Therapeutics Inc.
|
| Issue: | Common stock
|
| Amount: | $71.25 million
|
| Greenshoe: | $10,687,500
|
| Shares: | 3.75 million
|
| Price: | $19.00
|
| Warrants: | No
|
| Bookrunner: | BofA Merrill Lynch
|
| Co-managers: | Lazard Capital Markets LLC, Ladenburg Thalmann & Co. Inc. and Ascendiant Capital Markets, LLC
|
| Announcement date: | June 17
|
| Pricing date: | June 20
|
| Settlement date: | June 25
|
| Stock symbol: | Nasdaq: RPRX
|
| Stock price: | $19.20 at close June 19
|
| Market capitalization: | $367.36 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
